期刊文献+

^(131)I-chTNT结合外照射治疗实体瘤的实验研究 被引量:8

Combined ^(131)I-chTNT and external irradiation for solid tumors in mice
下载PDF
导出
摘要 目的:比较单用131I-chTNT与131I-chTNT结合外照射对荷瘤肺癌动物模型肿瘤生长影响的差异。方法:人鼠嵌合抗肿瘤细胞核单抗(chTNT-3)是针对肿瘤坏死组织的新型抗体,具有广谱的抗肿瘤作用,用131I标记单克隆抗体形成放射性螯合物。24只人肺腺癌荷瘤裸鼠分为4组,分别给予不同的治疗方案后比较肿瘤中24h放射活度比、肿瘤中放射活度比、平均累积吸收剂量以及累积吸收总量。结果:131I-chTNT联合外照射组,24h肿瘤放射活度比、肿瘤中放射活度比、平均累积吸收剂量以及累积吸收总量较单纯131I-chTNT组高(P<0.05),与对照组相比差异亦有统计学意义。结论:131I-chTNT结合外照射治疗实体瘤,在给药前行20Gy的外照射组其肿瘤中24h放射活度比、肿瘤放射活度比、平均累积吸收剂量、累积吸收总量高,有助于提高治疗效果。 Objective:To compare the difference of iodine-131-1abeled tumor necrosis therapy chimeric antibody(^131I-chTNT) and ^131 I-chTNT in combination with external irradiation for solid tumors mice. Methods:chTNT-3, a chimeric monoclonal antibody directed cell nucleus in the necrotic parts of tumor, could play important roles in many tumors, chTNT-3 was iodinated with ^131 I. Twentyfour nude mice with tumor cells xenografts( human adenocarcinoma of lung) used in the study ,were divided into six groups and given different treatment protocols. Total accumulated dose, 24h percentage of injected activity per gram of tumor tissue and accumulated dose per injected activity were compared between these different groups. Results: In the study, better yields in terms of total accumulated dose, 24h percentage of injected activity per gram of tumor tissue and accumulated dose per injected activity were seen in the first group. Conclusion:Enhanced effects can be achieved by combined external irradiation with radioimmunotherapy using the monoclonal anticytokeratin antibody ^131I-chTNT. 20Gy of external irradiation should be given prior to Mab injection.
出处 《临床肿瘤学杂志》 CAS 2007年第5期325-327,331,共4页 Chinese Clinical Oncology
基金 湖北省科技厅重点基金项目(2004AA304B08)
关键词 放射免疫治疗 人鼠嵌合抗肿瘤细胞核单抗 外照射 裸鼠 Radioimmunotherapy Iodine-131-1abeled tumor necrosis therapy chimeric antibody( ^131 I-chTNT) External irradiation Nude mice
  • 相关文献

参考文献6

  • 1Hornick JL,Sharifi J,Khawli LA,et al.Single amino acide substitution in the Fc region chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors[J].J Nucl Med,2002,41(2):355-362.
  • 2Ogura M.Progress in therapeutic strategy for malignant lymphoma a review[J].Gan To Kagaku Ryoho,2005,32(3):309-327.
  • 3Wygoda Z,Tarnawski R,Brady L,et al.Simultaneous radiotherapy and radioimmunotherapy of malignant gliomas with anti-EGFR antibody labelled with iodine 125[J].Nucl Med Rev Cent East Eur,2002,5(1):29-33.
  • 4Macklis RM.Radioimmunotherapy in a radiation oncology environment:building a multi-specialty team[J].Int J Radiat Oncol Biol Phys,2006,66(2 Suppl):4-6.
  • 5Sterzing F,Munter MW,Schafer M,et al.Radiobiological investigation of dose-rate effects in intensity-modulated radiation therapy[J].Strahlenther Onkol,2005,181(1):42-48.
  • 6Sugawara Y,Murase K,Kikuchi K,et al.Measurement of tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging and deconvolution analysis:a preliminary study in musculoskeletal tumors[J].J Comput Assist Tomogr,2006,30(6):983-990.

同被引文献66

引证文献8

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部